Contract Research
From Office of Health Economics
Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).
Access Statistics for this working paper series.
Is something missing from the series or not right? See the RePEc data check for the archive and series.
- 002377: A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases

- Maria Errea;Nadine Henderson;Chris Skedgel;Mireia Jofre-Bonet
- 002370: The Lower Drug Costs Now Act and Pharmaceutical Innovation

- Lou Garrison;Jake Hitch;Grace Hampson;Mireia Jofre-Bonet;Martina Garau;Graham Cookson
- 002359: Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making

- Marina Rodes Sanchez;Boris Rachev;Julia Spencer;Isha Sharma;Anupama Tantri;Rachel Mitrovich;Adrian Towse;Lotte Steuten
- 002344: Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective

- Mikel Berdud;Mireia Jofre-Bonet;Adrian Towse
- 002338: The Promise of Gene Therapies: Are We Ready?

- Office of Health Economics
- 002290: Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

- Nadine Henderson;Lotte Steuten
- 002284: A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold

- Mikel Berdud;Jimena Ferraro;Adrian Towse
- 002283: The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective

- Simon Brassel;Lotte Steuten
- 002282: Realising the Broader Value of Vaccines in the UK

- Simon Brassel;Margherita Neri;Phill O’Neill;Lotte Steuten
- 002280: NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?

- Mehmet Bulut;Phill O’Neill;Amanda Cole
- 002277: Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies

- Simon Brassel;Graham Cookson
- 002271: International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

- Kyann Zhang;Martina Garau
- 002268: Opportunities to Increase Efficiency in Healthcare

- Maria Errea;Chris Skedgel;Bernarda Zamora;Grace Hampson;Graham Cookson;Maria Errea;Rikard Althin;Thomas Hofmarcher;Peter Lindgren
- 002249: Meningococcal Vaccines: An International Comparison of Decision-Making Processes, Frameworks and Methodologies. Are Values Missing?

- Koonal Shah, Karla Hernandez-Villafuerte and Paula Lorgelly
- 002247: Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?

- Patricia Cubi-Molla;Maria Errea;Kyann Zhang;Martina Garau
- 002236: Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions

- Nadine Henderson;Maria Errea;Chris Skedgel;Mireia Jofre-Bonet
- 002201: Data Governance Arrangements for Real-World Evidence in Japan

- Hideo Yasunaga;Hayato Yamana;Adrian Towse
- 002197: Unrelieved Pain in Palliative Care in England

- Bernarda Zamora;Graham Cookson;Martina Garau
- 002108: Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

- Grace Hampson, David Mott, Nancy Devlin and Koonal Shah
- 002096: Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation

- Amanda Cole;Adrian Towse
- 002051: Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS

- Phill O’Neill;Adrian Towse;Jimena Ferraro
- 002047: The Impact of New Medicines in the NHS: 70 Years of Innovation

- Christopher Sampson
- 002023: Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology

- Koonal Shah;Mike Herdman;Yvonne Summers;Nancy Devlin;Patricia Cubi-Molla
- 002015: A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”

- Karla Hernandez - Villafuerte;Brendan Shaw;Adrian Towse
- 002009: The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

- Adrian Towse;Amanda Cole;Bernarda Zamora
- 001978: Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

- Adrian Towse;Martina Garau
- 001976: Barriers to Uptake of Minimal Access Surgery in the United Kingdom

- Christopher Sampson
- 001944: Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”

- Mikel Berdud;Adrian Towse;Jorge Mestre-Ferrandiz
- 001932: Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure

- Bernarda Zamora;Francois Maignen;Paula Lorgelly
- 001910: Data Governance Arrangements for Real-World Evidence: South Korea

- Amanda Cole;Eui-Kyung Lee;Jae-A Park;Jorge Mestre-Ferrandiz
- 001818: Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

- Bernarda Zamora;Phill O’Neill;Martina Garau;Francois Maignen;Jorge Mestre-Ferrandiz
- 001802: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?

- Grace Hampson;Adrian Towse
- 001743: Four Case Studies to Explore the Added Value of Oxford AHSN

- Grace Hampson;Bernarda Zamora;Adrian Towse;Adam Martin;Jo Exley
- 001699: Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making

- Patricia Cubi-Molla;Adrian Towse;Sarah Karlsberg-Schaffer;Nancy Devlin
- 001688: Assessing Trends in SMC Advice Decisions (October 2009- September 2015)

- Phill O’Neill;Bernarda Zamora
- 001660: Data Governance Arrangements for Real-World Evidence

- Amanda Cole;Adrian Towse;Lou Garrison;Jorge Mestre-Ferrandiz
- 001645: Estimation of Future Cases of Dementia from Those Born in 2015

- Fraser Lewis
- 001595: Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK

- Amanda Cole
- 001576: Do Respondents Completing Abstract, Hypothetical Priority-setting Exercises Agree With the Policy Implications of Their Choices?

- Koonal Shah;Nancy Devlin;Paul Barnsley;Amanda Cole
- 001504: Obstructive Sleep Apnoea: Health Economics Report

- Juan Carlos Rejon-Parilla;Martina Garau
- 000518: The Trajectory of Dementia in the UK - Making a Difference

- Fraser Lewis;Lesley Cockcroft;Phill O’Neill
- 000265: Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions

- Alastair Gray;Paul Fenn;Clive Pritchard;Ed Godber;Martina Garau;Adrian Towse
- 000236: Medical Research: What's It Worth?

- Office of Health Economics
- 000234: Assessment and Appraisal of Oncology Medicines: NICE's Approach and International HTA Experience

- Koonal Shah;Qing Wang;Michael F. Drummond;Anne R. Mason;Martina Garau;Adrian Towse
- 000229: Forward Together: Complementarity of Public and Charitable Research with Respect to Private Research Spending

- Jorge Mestre-Ferrandiz;Jon Sussex
- 000212: Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe

- Jorge Mestre-Ferrandiz;Ruth Puig-Peiro;Adrian Towse
- 000210: The Publicly Funded Vaccines Market in the UK

- Jon Sussex;Koonal Shah
- 000206: The Publicly Funded Vaccines Market in Australia

- Jon Sussex;Koonal Shah;Jim Butler
- 000203: Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society

- Jorge Mestre-Ferrandiz;Jon Sussex;Martina Garau;Phill O’Neill
- 000192: The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response

- Nancy Devlin;Emma Hawe;Lou Garrison;Adrian Towse
- 000187: Exploring the Interdependency between Public and Charitable Medical Research

- Arik Mordoh;Martina Garau
- 000169: Time Trends in NICE HTA Decisions

- Nancy Devlin;Ruth Puig-Peiro;Phill O’Neill
- 000144: International Comparisons of Medicines Prices: 2011 Indices

- Ruth Puig-Peiro;Jorge Mestre-Ferrandiz;Jon Sussex;Phill O’Neill
- 000050: The Expanding Value Footprint of Oncology Treatments

- Juan Carlos Rejon-Parilla;Karla Hernandez-Villafuerte;Koonal Shah;Jorge Mestre-Ferrandiz;Lou Garrison;Adrian Towse
- 000001: Health and the Use of Medicines in Primary Care in Wales

- Lesley Cockcroft;Emma Hawe;Rick Greville;Phill O’Neill